Global Central Nervous System Partnering 2014 to 2021: Deal trends, players and financials


The Global Central Nervous System Partnering 2014 to 2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the central nervous system (cns) partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
October 2021
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Global Central Nervous System Partnering 2014 to 2021 provides the full collection of Central Nervous System disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.


  • Trends in Central Nervous System partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Central Nervous System partnering agreement structure
  • Central Nervous System partnering contract documents
  • Top Central Nervous System deals by value
  • Most active Central Nervous System dealmakers


Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.


The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.


The report presents financial deal terms values for Central Nervous System deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.


The initial chapters of this report provide an orientation of Central Nervous System dealmaking trends.


Chapter 1 provides an introduction to the report.


Chapter 2 provides an overview of the trends in Central Nervous System dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.


Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.


Chapter 4 provides a review of the leading Central Nervous System deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Central Nervous System dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 5 provides comprehensive access to Central Nervous System deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2014. The chapter is organized by specific Central Nervous System therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided with each report of all Central Nervous System partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Central Nervous System partnering and dealmaking since 2014.  


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Central Nervous System technologies and products.


Report scope


Global Central Nervous System Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Central Nervous System trends and structure of deals entered into by leading companies worldwide.


Global Central Nervous System Partnering 2014 to 2021 includes:


  • Trends in Central Nervous System dealmaking in the biopharma industry since 2014
  • Analysis of Central Nervous System deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Central Nervous System deal contract documents
  • Comprehensive access to Central Nervous System deal records
  • The leading Central Nervous System deals by value since 2014
  • Most active Central Nervous System dealmakers since 2014


The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson's disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.


In Global Central Nervous System Partnering 2014 to 2021, available deals and contracts are listed by:


  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Central Nervous System Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for central nervous system deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Central Nervous System Partnering 2014 to 2021 provides the reader with the following key benefits:


  • In-depth understanding of Central Nervous System deal trends since 2014
  • Access Central Nervous System deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Central Nervous System partner companies
  • Comprehensive access to links to actual Central Nervous System deals entered into by the world’s biopharma companies
  • Indepth review of Central Nervous System deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Central Nervous System opportunities
  • Uncover companies actively partnering Central Nervous System opportunities

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Central Nervous System dealmaking


2.1. Introduction

2.2. Central Nervous System partnering over the years   

2.3. Central Nervous System partnering by deal type

2.4. Central Nervous System partnering by industry sector

2.5. Central Nervous System partnering by stage of development

2.6. Central Nervous System partnering by technology type

2.7. Central Nervous System partnering by therapeutic indication


Chapter 3 –Financial deal terms for Central Nervous System partnering


3.1. Introduction

3.2. Disclosed financials terms for Central Nervous System partnering

3.3. Central Nervous System partnering headline values

3.4. Central Nervous System deal upfront payments

3.5. Central Nervous System deal milestone payments

3.6. Central Nervous System royalty rates


Chapter 4 – Leading Central Nervous System deals and dealmakers


4.1. Introduction

4.2. Most active in Central Nervous System partnering

4.3. List of most active dealmakers in Central Nervous System   

4.4. Top Central Nervous System deals by value


Chapter 5 – Central Nervous System contract document directory


5.1. Introduction

5.2. Central Nervous System partnering deals where contract document available


Chapter 6 – Central Nervous System dealmaking by therapeutic target


6.1. Introduction

6.2. Deals by Central Nervous System therapeutic target




Appendix 1 – Directory of Central Nervous System deals by company A-Z since 2014

Appendix 2 – Directory of Central Nervous System deals by deal type since 2014

Appendix 3 – Directory of Central Nervous System deals by stage of development since 2014

Appendix 4 – Directory of Central Nervous System deals by technology type since 2014

Further reading on dealmaking

Deal type definitions


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from CurrentPartnering


Table of figures


Figure 1: Central Nervous System partnering since 2014

Figure 2: Central Nervous System partnering by deal type since 2014

Figure 3: Central Nervous System partnering by industry sector since 2014

Figure 4: Central Nervous System partnering by stage of development since 2014

Figure 5: Central Nervous System partnering by technology type since 2014

Figure 6: Central Nervous System partnering by indication since 2014

Figure 7: Central Nervous System deals with a headline value

Figure 8: Central Nervous System deals with upfront payment values

Figure 9: Central Nervous System deals with milestone payment

Figure 10: Central Nervous System deals with royalty rates

Figure 11: Active Central Nervous System dealmaking activity since 2014

Figure 12: Top Central Nervous System deals by value since 2014

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1ST Biotherapeutics, 2M, 3M Drug Delivery Systems, 3PrimeDx, 3SBio, 4SC Discovery, 7D Surgical, 23andMe, A&B Company, A*STAR Agency for Science, Technology and Research, Aarhus University Hospital, Abbott Laboratories, Abbvie, AbCellera, Abeona Therapeutics, Abide Therapeutics, Ablynx, Ab Medica, Abzena, ACADIA Pharmaceuticals, Accelerated Cure Project for MS, Accelovance, Accera Pharmaceuticals, Acella Pharmaceuticals, Acelrx Pharmaceuticals, Acerus, Acetylon Pharmaceuticals, AC Immune, Acorda Therapeutics, Actavis (acquired by Watson), Actelion, Acticor Biotech, Acturum Life, Acura Pharmaceuticals, AcuraStem, AdAlta, Adamas Pharmaceuticals, Adaptive Health, Adare Pharmaceuticals, Addex Therapeutics, Adept Neuro, Advanced Cooling Therapy, Advanced Technologies Solutions, Advantage Consumer Healthcare, Adventus Ventures, Aeon Bioscience, Aequus Pharmaceuticals, Aeromics, AEterna Zentaris, Aethlon Medical, Affilogic, AFFiRiS, Afraxis, AFT Pharmaceuticals, AgeX Therapeutics, Agilent Technologies, Agilis Biotherapeutics, Aguettant, Aichi Medical University, Aiforia Technologies, AiPing Pharmaceutical, AirWare Labs, AKC Canine Health Foundation, Akorn, Akrimax Pharmaceutical, Albany Molecular Research, Alberta Health Services, Albert Einstein College of Medicine, Alcyone Lifesciences, Alder Biopharmaceuticals, Alector, Aleva Neurotherapeutics, Alexion Pharmaceuticals, Alexza Pharmaceuticals, Alfa Wassermann, AliveGen, Alkahest, Alkermes, Allen Institute for Brain Science, Allergan, Allergan (name changed from Actavis), Allied Healthcare Products, Alnylam Pharmaceuticals, ALS Association, Alseres Pharmaceuticals, ALS Finding a Cure Foundation, Altair, AltaML, Altus Formulation, AlzeCure Pharma, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Alzheimers Research UK, Amarantus BioSciences, Ambra Health, Ambu, Amedica, Amendia, American Academy of Neurology, American Association of Neuromuscular & Electrodiagnostic Medicine, American College of Emergency Physicians, American College of Physicians Foundation, American Heart/Stroke Association, American Heart Association, American Migraine Foundation, American National Multiple Sclerosis Society, American Parkinson Diseases Association, American Speech-Language-Hearing Association, Amgen, Amicus Therapeutics, Amneal Pharmaceuticals, AmorChem, Amydis Diagnostics, Amylgen, AnaBios, Analytical Testing Laboratory, Anavex Life Sciences, ANI Pharmaceuticals, Annette Funicello Research Fund for Neurological Diseases (AFRFND), Annovis Bio, AnthroTronix, Antibe Therapeutics, Antidote, Aphios, ApiFix, Appello Pharmaceuticals, AppliedVR, APR Applied Pharma Research, APRINOIA Therapeutics, Aptahem, Aptinyx, Aquinnah Pharmaceuticals, Aralez Pharmaceuticals, Aratana Therapeutics, arGEN-X, Arizona State University, ArmaGen, Array Biopharma, Arteaus Therapeutics, Artelo Biosciences, Arterys, Arvelle Therapeutics, Asahi Kasei, Asana Biosciences, Ascend Therapeutics, Asceneuron, AskAt, Asklepios Biopharmaceutical, Aspen Holding, Assertio Therapeutics, Association for Frontotemporal Degeneration, Astellas Pharma, Astellas Pharma Europe, Asterias Biotherapeutics, Astex Pharmaceuticals, AstraZeneca, ATAI Life Sciences, Atara Biotherapeutics, Ataxion, Athersys, Atnahs Pharma, Aucta Pharmaceuticals, Aural Analytics, Aurora Cannabis, Austin Health, Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), Australian Research Council, Avanos Medical, Avella, Avenue Therapeutics, AveXis, Axial Biotherapeutics, AXIM Biotechnologies, AxoSim, Axovant Gene Therapies, Axsome Therapeutics, Axxess Pharma, Aziyo Biologics, Azova, Bachem, Bachmann-Strauss Dystonia & Parkinson Foundation, Baergic Bio, Bain Capital, Banyan Biomarkers, Baudry Laboratory, Baxter International, Bayer, Baylor College, Baylor College of Medicine, B Braun, BD Consultancy, Becton Dickinson, Beijing Leadman Biochemistry, Ben-Gurion University, BenevolentAI, Benvenue Medical, Berg, Best Choice, Beyond Batten Disease Foundation, Bhang, Bial, BIA Separations, Biedermann Motech, Bio-Techne, BioArctic Neuroscience, biOasis Technologies, BioAxone Therapeutic, Biocodex, Biocomposites, BIOCORP, BioCrossroads, Biodextris, Biodirection, Biofourmis, Biogen, Biohaven Pharmaceutical Holding, Biohealth Innovation, Bioinn Molecular Diagnosis, BioLamina, BiolineRX, BioMarin Pharmaceutical, Biomedical Advanced Research and Development Authority, BioMedical Research, BioMed X Innovation Center, BioMotiv, Bionik Laboratories, Bionomics, Bionure, Biopharmaceuticals Australia, BioQ Pharma, Bioscience Pharma Partners, Bioservo Technologies, BioSpring, BioSyent Pharma, BioTie Therapies, Biotoscana Farma, Biscayne Neurotherapeutics, BL&H, Blackfynn, Blackrock Microsystems, Blackrock NeuroMed, Blackstone Medical, BlackThorn Therapeutics, Blinktbi, Bloom Science, BlueRock Therapeutics, Boehringer Ingelheim, Boston Scientific, Boston University, Boston University School of Medicine, Bpifrance, Bracket, Braeburn Pharmaceuticals, Brain and Spine Institute, BRAINBox Solutions, BRAIN Initiative, BrainLAB, Brainomix, BrainScope, BrainStorm Cell Therapeutics, Brainsway, Brain Treatment Center San Diego, Brammer Bio, Breathe Active, BridgeBio Pharma, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Brooks Automation, Brown University, Bruker, C2N Diagnostics, C4 Therapeutics, C4X Discovery, Cactus Semiconductor, Cadence Biomedical, Cadence Pharmaceuticals, Cadila Pharmaceuticals, Cal-BRAIN, Calico, California Institute for Biomedical Research, California Institute for Regenerative Medicine, California Institute of Technology, Calmare Therapeutics, Calox de Costa Rica, Camargo Pharmaceutical Services, Camarus, Cambridge Cognition, Cambridge Commodities, Camino Partnership, CAMP4 Therapeutics, Canadian Institutes of Health Research, Canadian Physiotherapy Association, Canbex Therapeutics, Canigma, CannaKids, CannaRoyalty, Canntab Therapeutics, Cannvalate, Canon Virginia, Canopy Growth, Cantabio Pharmaceuticals, Capnia, Caprion Proteomics, Caputron Medical, Caraway Therapeutics, Cardiff University, Cardiovascular Solutions of Central Mississippi, Carestream Health, Caretta Therapeutics, Carl Zeiss, Carmot Therapeutics, Carna BioSciences, Carnegie Mellon University, Carrum Health, Case Western Reserve University, Casma Therapeutics, CAS Medical Systems, Castle Creek Pharmaceuticals, Catalent, Catalyst Pharmaceutical Partners, CavoGene LifeSciences, CBD Solutions, Cedars-Sinai Medical Center, CEFALY Technology, CEITEC, Celgene, Cell and Gene Therapy Catapult, Cellectricon, Celltrion, Cellular Dynamics International, Cellvation, Censo Biotechnologies, Center for iPS Cells Research and Application, Center for Sensorimotor Neural Engineering, Center for Technology and Innovation in Pediatrics (CTIP), Center for the Advancement of Science in Space, Centinel Spine, Centogene, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Drug Research and Development (CDRD), Centre Hospital University - Bordeaux, Centrexion, Centro de Investigación Biomédica en Red de Salud Mental, Century Medical, Cephagenix, CerebraCell, Cerebral Therapeutics, Cerecor, CereHealth, Cerevel Therapeutics, CerSci Therapeutics, Certainty Health, Certara, Cerus Endovascular, Cerveau Technologies, Cervel Neurotech, Champalimaud Foundation, Chaperone Technologies, Charcot-Marie-Tooth Association, Charles River Associates, Charles River Laboratories, Charleston Laboratories, ChemDiv, ChemoCentryx, Children's Hospital at Montefiore, Children's Hospital Boston, Children's Hospital of Pittsburgh Foundation, Children's Hospital Of Wisconsin, Children's Minnesota, Children's Research Institute, ChoiceSpine, Christie Medical, Christopher & Dana Reeve Foundation, Chromocell, Chronos Therapeutics, Chugai Pharmaceutical, Cincinnati Children’s Hospital Medical Center, Cipher Pharmaceuticals, Cipla Medpro, Circuit Therapeutics, Citizens United for Research in Epilepsy, City of Hope, Clene Nanomedicine, Cleveland Clinic, Cleveland Diabetes Care, Clevexel Pharma, Clinatec, Clinical Ink, Clinical Laserthermia Systems (CLS), Clinical Network Services, Clinigen, Clinipace Worldwide, Clinvest, Cloud Pharmaceuticals, CluePoints, Coala Life, Cobra Biologics, CODA Biotherapeutics, Codiak BioSciences, Cofactor Genomics, Cognition Therapeutics, CogState, Cohen Veterans Bioscience, Colby College, Colgate University, Collegium Pharmaceuticals, Colorado HealthOP, Columbia University, Columbia University Medical Center, CombiGene, Compassionate Care Center of New York, Compass Point Research, Complement Pharma, Compumedics, Concordia Healthcare, Confo Therapeutics, Congenica, Congressman Chaka Fattah, Context Therapeutics, Convelo Therapeutics, Convergence Pharmaceuticals, Cook Biotech, Corbin Therapeutics, Corestem, Corium International, Coronado Biosciences, Corsair Innovations, CorTechs Labs, Cortexyme, Corvida Medical, Courtagen Life Sciences, Covis Pharmaceutical, Cranford Pharmaceuticals, CRC Health, Creatori Health, CRISPR Therapeutics, Cronos Group, Crossbeta Biosciences, Crown Laboratories, CSPC Pharmaceutical Group, Cumberland Pharmaceuticals, CURE Pharmaceutical, Currax Pharmaceuticals, Custopharm, CVR Global, Cyclenium Pharma, Cycle Pharmaceuticals, Cyclica, Cyclofluidic, Cynapsus Therapeutics, Cypher Genomics, Cypralis, Cytocom, Cytokinetics, Cytox, Cyxone, Daiichi Sankyo, Dainippon Sumitomo Pharma, Dalhousie University, Dana-Farber Cancer Institute, DEARhealth, Defense Advanced Research Projects Agency, Defense Logistics Agency, Dekel Pharmaceuticals, Denali Therapeutics, Denovo Biopharma, Department of Defense, Department of Health and Human Services, Department of Veterans Affairs, DepoMed, DePuy, Desma HC, DiaMedica, DiamiR, Dicerna Pharmaceuticals, Diego Pellicer, Dixi, DJO Global, DKSH, Doctor’s Medical, Domain Therapeutics, Dong-A Pharmaceutical, Dong-A ST, Dr. Reddy's Laboratories, Dr. Stephen Cook, Draeger Safety Diagnostics, Dragonfly Therapeutics, DrChrono, DuChemBio, Duke-NUS Graduate Medical School Singapore, Duke University, Durect, DyNAbind, Dystonia Europe, DZNE German Center for Neurodegenerative Diseases, E-Scape Bio, E-Therapeutics, Eagle Pharmaceuticals, Early Signal Foundation, Eastar Industries, ECM Therapeutics, EDAP TMS, Edge Therapeutics, Editas Medicine, Edith Cowan University (ECU), eemagine, Egalet, EicOsis, Eisai, Eisai Inc, Ekso Bonics, ELC Group, Electrical Geodesics, ElectroCore, Elekta, Eli Lilly, Elite Pharmaceuticals, ElMindA, Elucid Bioimaging, Ember Therapeutics, EMD Serono, EmergeOrtho, EMMAC Life Sciences, Emory University, Empatica, EMS, EMTensor, Emulate, Enamine, Encoded Therapeutics, Endo International, Endonovo Therapeutics, Endo Pharmaceuticals, Endotronix, eNeura Therapeutics, Engage Therapeutics, Enigma Biomedical, Entia Biosciences, Epic Pharmaceuticals, Epilepsy Foundation (EF), Epilepsy Society, EPS International, Erisyon, Essex Bio-Technology, Esteve, Eton Pharmaceuticals, Eureka Eurostars, Euroimmun, European Commission, European Parkinson's Disease Association, European Union, Europe Technologies, Eversana, Evidation Health, Evogen, Evotec, Ewopharma, Exactech, Exagen Diagnostics, Exeltis, Exosome Sciences, Expesicor, Ezose Sciences, F-Star, FAAH Pharma, Facial Pain Research Foundation, Fast Forward, FastFunds Financial, Federal Ministry of Education and Research (BMBF), Feinstein Institute for Medical Research, Ferring Pharmaceuticals, FightMND, Firsthand Technology, Fitabase, FitBit, Flexion Therapeutics, Flint Rehabilitation Devices, Florey Institute of Neuroscience and Mental Heath, Florida Atlantic University Research, Flowonix, Flywheel, Fondazione Telethon, Food and Drug Administration (FDA), Forbius, Forest Pharmaceuticals, FORMA Therapeutics, Formsense, Fortress Biotech, Forward Pharma, Fosun Pharmaceutical, Foundation For Angelman Syndrome Therapeutics, Foundation for Mitochondrial Medicine, Foundation for the National Institutes of Health (FNIH), Fresenius Kabi Pharmaceuticals, Fritz Clinic, FSD Pharma, Fudan University, Fukuda Denshi, Fundacion Universidad Torcuato Di Tella, Fuzionaire Diagnostics, Gain Therapeutics, Galapagos, Galen, Galena Biopharma, GB Sciences, GE Healthcare, Geisinger Medical Center, Genea Biocells, GeneData, Genentech, General Electric (GE), Gene Therapy Research Institution, Genethon, GeNeuro, Genmab, Genomics, Genomind, Genpharm, Genzyme, Geo-Med, George Washington University, Georgia Institute of Technology, Gestion Univalor, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, Glialogix, Global Alliance for Innovation in Neuroscience, Global Drug Development Centre (GDCC) China, Global Kinetics, GM Medical, GNS Healthcare, Gold Coast Therapeutics, Golden Meditech, Goodwin Biotechnology, Google, Government of Canada, Graminex, Grand Valley State University, Greatbatch, Great Ormond Street Hospital (GOSH), Grunenthal, Grupo Juste, GW Pharmaceuticals, Hadassah Medical Center, Hainan Sihuan Pharmaceutical, Hainan Sinotau Pharmaceutical, Hannover Medical School, Happify Health, HAPPYneuron, Harvard Medical School, Harvard Pilgrim Health Care, Harvard Stem Cell Institute, Harvard University, Hawaii Biotech, Healios K.K., Healthcare Royalty Partners, HealthTrust, HealthWarehouse, Healthy Directions, Healthy Focus, Healx, Heart Rhythm Society, HeartScore, HEC Pharm, Helius Medical Technologies, Helmholtz Zentrum Munchen, Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center, Hennepin County Medical Center, Hennig, Henry Ford Health System, Henry L. Hillman, Hertie Foundation, Hesperos, Hetero Labs, Hi-Tech Pharmacal, Hikma Pharmaceuticals, Hitachi Chemical, HitGen, Hoba Therapeutics, Hobbs Rehabilitation, Hoffmann La Roche, Holmdel Pharmaceuticals, Homology Medicines, Honda R&D Americas, Hong Kong Baptist University, Horizon 2020, Horizon Discovery, Horizon Pharma plc, Hospital Fondation Adolphe de Rothschild, Hospital for Special Surgery, Howard Hughes Medical Institute (HHMI), Hydra Biosciences, HypGen, I-mab, iBio, iBIO Institute’s PROPEL Center, IBM, Icagen, Icahn School of Medicine at Mount Sinai, IDbyDNA, Ideal Medical Solutions, IDIPharma, Idorsia, Imago Pharmaceuticals, Imanova, Imbrium Therapeutics, ImmunArray, Immuneering, Immune Pharmaceuticals, Immune Therapeutics, ImmuNext, Impax Laboratories, Impel NeuroPharma, Imperial College London, Implanet, Inception 5, Inception Sciences, InCube Labs, India Globalization Capital, Indiana University, Inexia, Infinity Pharmaceuticals, Inflazome, Infosys Technologies, InfraScan, InfuTronix Solutions, Inhibikase Therapeutics, Innara Health, Innosuisse, Innovate UK, iNova Pharmaceuticals, Inoviem Scientific, Inovio Pharmaceuticals, Inscopix, Inserm, Inserm Transfert, InSightec, In Silico Biosciences, InspireMD, Inspyr Therapeutics, Institute for Research in Biomedicine, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute for the Promotion of Innovation by Science and Technology in Flanders, Institute of Biophysics, Institute of Genetics and Molecular and Cellular Biology, Insys Therapeutics, Intec, Integra LifeSciences, Integrity Implants, Intel, IntelGenx, IntelliCell BioSciences, Intellipharmaceutics, Intellirod Spine, Interleukin Genetics, InteRNA Technologies, International Progressive MS Alliance, International Security Group, International Society for Neurovascular Disease (ISNVD), International Stem Cell, Interventional Spine, InteRx Biomedical, inVentiv Health, Invion, Invitae, InVivo, InVivo Therapeutics, Ionis Pharmaceuticals, IONTAS, Io Therapeutics, Ipsen, Iroko Pharmaceuticals, Iron Horse Diagnostics, Irras, iSchemaView, Isomerase Therapeutics, Israeli National Authority for Technological Innovation, Italian Multiple Sclerosis Society, Itonis, Ives EEG Solutions, IXICO, Jackson Laboratory, James S. McDonnell Foundation, Jan Medical, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Tobacco, Jazz Pharmaceuticals, JCR Pharmaceuticals, Jiangsu NHWA Pharmaceutical, Jinzhou Ahon Pharma, Jnana Therapeutics, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Joint Solutions Alliance, Jubilant Biosys, Jubilant Hollisterstier, Juno Biomedical, K2M, Kadimastem, Kairuku, Kaiser Permanente, Kaldi Pharma, KannaLife Sciences, Karolinska Institute, Karyopharm Therapeutics, Kavli Foundation, KBI BioPharma, Keck School of Medicine of USC, Kelyniam Global, KemPharm, Kessler Foundation, Keystone Heart, Kindred Healthcare, KineMed, Kineta, Kinetic Concepts, Kings College London, Klaria, Knight Therapeutics, Knopp Biosciences, Knox College, Konica Minolta, Kurve Technology, KVK-Tech, Kwangwon, Kyocera, Kyoto University, Laboratoire Gamida, Laboratorios Adler, LABORATORIOS SAVAL, Lacerta Therapeutics, Lancet, Landsteiner Scientific, Lannett, Lauren Sciences, Lawson Health Research Institute, LDR Holding, Leading Edge Pharms, Legacy Of Angels Foundation, Leica Microsystems, Leiters, Les Laboratoires Servier, Lexicon Pharmaceuticals, LGS Foundation, Lieber Institute, LifeArc, Lifehealthcare, Ligand Pharmaceuticals, Lineage Cell Therapeutics, LineaRx, Link Health, LipoCure, Litha Pharma, Lobsor Pharmaceuticals, Longevity Biotech, Lonza, Los Altos Pharmaceuticals, Lotus Pharmaceuticals, Louisiana State University, Lpath, Luciole Medical, Ludwig Institute for Cancer Research, Luitpold Pharmaceuticals, Lumicera Health Services, Lumosa Therapeutics, Lunatus, Lundbeck, Lund University, Lurie Children's Hospital of Chicago, Luxna Biotech, Lyfebulb, Lysogene, Lysosomal Therapeutics, M.Fast Technologie, Macquarie University, Macrogenics, Magic Leap, MAGiQ Therapeutics, Magnetic Insight, Magniant, Magstim, Maitland Labs, Mallinckrodt Pharmaceuticals, Maness Veteran Medical, Mapi Pharma, Marathon Pharmaceuticals, Marina Biotech, Marnier-Lapostolle Foundation, Maruho, Masimo, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mast Therapeutics, MaxQ AI, Mayne Pharma, Mayo Clinic, Mazor Robotics, MBA, MC10, McGill University, McNeil Consumer Pharmaceuticals, Mdoloris Medical Systems, MDS Pharma Services, MedGenesis Therapeutix, Medica Labs, Medical Developments International, Medical Innovators, Medical Research Council, Medical University of Innsbruck, Medical University of Vienna, Medical University South Carolina, MediCann Handels, Medicrea, Medidata Solutions, MedImmune, Mediolanum, Mediso, Medison Pharma, Medline Industries, Medopad, Medosome Biotec, Medovex, MedPharm, Medtronic, MedyMatch, Meiji Seika, MeiraGTx, MellingMedical, Memorial Sloan Kettering Cancer Center, MentiNova, Merck and Co, Merck Serono, Meridian Medical Technologies, Mesoblast, MetP Pharma, Metrion Biosciences, MetVital, MGC Pharma, Michael J Fox Foundation, Michigan State University, MicroConstants, Microsoft, Migranade, MilliporeSigma, MindImmune Therapeutics, Mindstrong Health, Minnesota Department of Health, Minnetronix, miRagen Therapeutics, Mission Therapeutics, MIT, Mitochon Pharmaceuticals, Mitsubishi Tanabe Pharma, MNX, Moberg Pharma, Moebius Medical, Moksha8, Molecular Health, Molecular Stethoscope, Molteni Farmaceutici, Momenta Pharmaceuticals, Monash University, Montreal Neurological Institute-Hospital, Morgan Stanley, Morphic Therapeutic, Mount Holyoke College, Mount Sinai Medical Center, MRIGlobal, MRI Interventions, MultiCorp International, Mundipharma, MURANAKA Medical Instruments, Muscle Activation Technique, Muscular Dystrophy Association, Myelin Repair Foundation (MRF), Myeloproliferative Neoplasm Research Consortium, MyHealios, Mylan Laboratories, Mylan Pharmaceuticals, MyndTec, Myomo, MyTPI, Nanna Therapeutics, Nanologica, NanoVibronix, Nanovis, Nansen Neuroscience Network, NantHealth, National Center for Advancing Translational Sciences (NCATS), National Heart, Lung and Blood Institute, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Disability and Rehabilitation Research, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Institutes of Health Center for Regenerative Medicine, National Medical Products, National Organization for Rare Disorders, National Parkinson Foundation (NPF), National Physical Laboratory, National Research Council Canada, National Research Council Industrial Research Assistance Program, National Science Foundation, National Stem Cell Foundation, National Surgical Care, National Yang-Ming University, Naurex, Navidea Biopharmaceuticals, Navitas, NDA Partners, Nencki Institute, Neos Therapeutics, NeoSync, Nephron Dx, Nephron Pharmaceuticals, Neptune Technologies & Bioressources, NeuCyte, Neumentum, NeurAegis, Neuraltus Pharmaceuticals, Neuraly, Neuralynx, NeurAxon, Neuren Pharmaceuticals, NeurExo Sciences, Neurexpert, Neurimmune Therapeutics, Neurim Pharmaceuticals, Neuro Assessment Systems, NeuroBo Pharmaceuticals, NeuroCog Trials, Neurocrine Biosciences, NeuroCycle Therapeutics, Neurogene, NeuroLogica, NeuroMetrix, NeuroMuscular Orthotics, Neuron-Experts, Neuronasal, Neuronoff, NeuroOne, NeuroPace, Neuropore Therapies, NeuroScience Associates, NeuroSearch, NeuroSigma, Neurosoft, NeuroTheryX, NeuroTracker, NeuroTrauma, Neurotrope BioScience, NeuroVigil, NeuroVive Pharmaceutical, NeuRx Pharmaceuticals, Neuway Pharma, NeuX Technologies, Nevro, New York Genome Center (NYGC), New York State, New York University, New York University School of Medicine, Nexeon MedSystems, Nexstim, Nexvet, NFANT Labs, NHL Alumni Association, NHS Bio, Nico, Nihon Kohden, Nikkan Pharma, Nikon CeLL Innovation, NineteenGale Therapeutics, Nippon Shinyaku, Nitrome Biosciences, nLife Therapeutics, Noninvasix, North Carolina State University, Northeast ALS Consortium, Northeastern University, Northern Biomedical Research, Northern California Institute for Research and Education, North Med, NorthShore University HealthSystem, Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, Nortis, Novartis, NovaSAID, Novation, Novici Biotech, NovImmune, Novogen, Novo Nordisk, Novoron Bioscience, Nuevolution, Nuformix, numares, Numerate, Nutra Pharma, Nutriband, NuVasive, Nuvectra, Nuviant Medical, Nuvo Pharmaceuticals, Nuvo Research, Nvidia, NYU Langone Medical Center, NYU Medical Center, Oakrum Pharma, Oblique Therapeutics, Occidental College, Ocular Therapeutix, Ohio State Innovation Foundation, Ohio State University, Oklahoma Health Care Authority, Oklahoma Medical Research Foundation, Olaris, Olea Medical, Oncodesign, OnDosis, OnFace, Ono Pharmaceutical, ON Semiconductor, Ontario Brain Institute (OBI), Opisafe, OptiKira, OptiNose, Orapharma, Oregon Health Sciences University, Oregon State University, Origent Data Sciences, Orion, Orphazyme, Ortho-Clinical Diagnostics, Orthofix, Ortho Kinematics, Osiris Therapeutics, Oska Wellness, Oslo University Hospital, Osseus Fusion Systems, Ossianix, Osteomed, Otsuka, Ovensa, Ovid Therapeutics, Oxford Biodynamics, Oxford BioMedica, Ozop Energy Solutions, Pace Wellness, Pacific Medical, Padlock Therapeutics, Pain Care Labs, Pain Relief & Wellness Strategy Center, Pain Therapeutics, Pairnomix, Pais Vasco University, Panaxia, Panion, Paolo and Marlene Fresco Foundation, Paragon Bioservices, ParcelShield, Parkinson's Disease Foundation, Parkinson's Institute, Parkinson's Institute and Clinical Center, Parkinson's UK, Par Pharmaceutical, Particle Sciences, Passage Bio, Patheon, PathMaker Neurosystems, Patient-Centered Outcomes Research Institute (PCORI),, Paul G Allen Family Foundation, Pax Neuroscience, PDL BioPharma, PEAR Therapeutics, Peking University, Pennsylvania State University, Pentax, Peptide Logic, Peptron, PeriGen, Pernix Therapeutics, Perrigo, PETNET Solutions, Pfizer, Pfizer Japan, PGI Drug Discovery, PharmaCielo, Pharmanest, Pharma Scientific Research, Pharmatronic, Pharmazz, PharMEDium, Pharmstandard, Pharnext, PhoreMost, PhytoTech Medical, PicnicHealth, Pierre Fabre, Piramal, PixarBio, Plagens Medical Consultants, Plandai Biotechnology, Plex Pharmaceuticals, Polpharma, Pomona College, Poseida Therapeutics, Pozen, PPD, Prana Biotechnology, Praxis, Prayog Labs, Precision Spine, Premier Biomedical, Premier Inc, Preora Diagnostics, Prevacus, Prevail Therapeutics, PreveCeutical Medical, Prevent Biometrics, Primary Peptides, Prime Therapeutics, Principia Biopharma, PrinterPrezz, Prism Health Care Services, Prize4Life, Pro-Tech Design and Manufacturing, Proclara Biosciences, Progenerative Medical, Progentec Diagnostics, Project ALS, Promenade Software, Prometheus Laboratories, Promimic, ProMIS Neurosciences, Pronto Diagnostics, Proove Biosciences, Prosenex, Prosetta Biosciences, ProterixBio, Proteus, ProTrade Systems, Protxx, ProvideGx, Proximagen Group, Proximagen Neuroscience, Proximo Medical, PsychoGenics, PTC Therapeutics, Puramed Bioscience, Purdue Pharma, Purdue Research Foundation, PureTech Health, Q-State Biosciences, Q30 Innovations, QB3@953, Q Therapeutics, Quadrant Biosciences, QuantalRF, Quanterix, Quartet Medicine, Queensland Institute of Medical Research (QIMR), QuiO Technologies, QurAlis, R-Tech Ueno, Radboud University Nijmegen Medical Centre, Rady Children's Institute for Genomic Medicine, Rafa Pharmaceuticals, Raffles PharmaTech, Rainbow Medical, Ramot at Tel Aviv University, RapidAI, Raptor Pharmaceutical, RaQualia Pharma, RDD Pharma, ReadCoor, ReadSense Genomic Center, Recipharm, Recordati, Recro Pharma, RedHill Biopharma, Redox, Regenacy Pharmaceuticals, Regenerative Medicine of China, Regenerative Medicine of Latin America, Regeneron Pharmaceuticals, Regeneus, RegenLab, Regenstrief Institute, Regents of the University of Michigan, Regenxbio, ReGenX Biosciences, Regulus Therapeutics, Relief Therapeutics, Relmada Therapeutics, Remedy Pharmaceuticals, Renhe, Renovis, ReproCell, Research Institute of the Hospital Universitari Vall d'Hebron, Reset Therapeutics, Retrotope, Rett Syndrome Research Trust, Revance Therapeutics, Revogenex, ReWalk Robotics, RH Nanopharmacuticals, Rich Pharmaceuticals, Riddell, Rio Grande Neurosciences, Rising Pharmaceuticals, RMX Biopharma, Roche, Rocket Science Health, Rockland Immunochemicals, Rodin Therapeutics, RogCon Biosciences, Rosetta Genomics, Roxro Pharma, Royal Philips Electronics, Royalty Pharma, Roy J. Carver Center for Genomics (CCG), RPRD Diagnostics, RTI Surgical, Rugen Therapeutics, Rutgers Cancer Institute of New Jersey, Rutgers University, RXi Pharmaceuticals, Sabal Therapeutics, Sabin Vaccine Institute, SAB Therapeutics, SafeWire, Sage Bionetworks, Sailing Sclerosis Foundation, Saint Louis University, Salix Pharmaceuticals, Samsung Biologics, SanBio, Sandoz, Sanford Burnham Institute, Sangamo BioSciences, Saniona, Sanofi, San Raffaele Hospital, San Raffaele Telethon Institute for Gene Therapy, Sarepta Therapeutics, Sawai Pharmaceuticals, Scholar Rock, Schrodinger, ScinoPharm Taiwan, Scopus BioPharma, Scripps Research Institute, SeaSpine, Secarna Pharmaceuticals, Sedor Pharmaceuticals, Seelos Therapeutics, Seikagaku, Seizure Tracker, Selexis, Sellas Clinicals Holding, Selvita, Senexta, Senhwa Biosciences, Sentio, Sentynl Therapeutics, Seqirus, SeraNovo, Seurat Therapeutics, Shandong Weigao Orthopedic Device, Shandong Xinhua Pharmaceutical, Shanxi Yabao Pharmaceutical Distribution, Sharp Edge Labs, Shenzhen Hybio Pharma, Shepherd Center, Shionogi, Shire Pharmaceuticals, Si-Bone, Siemens Healthineers, Signet International, SilverCloud Health, Simcere Pharmaceuticals, Sintact Medical Systems, Sirenas, Sirion Biotech, SiteOne Therapeutics, Sites Medical, SIT Laboratorio Farmaceutico, SK Biopharmaceuticals, Skyhawk Therapeutics, Skyland Analytics, Skyline Vet Pharma, Small Business Innovation Research, Soin Neuroscience, Solaris, Solasia Pharma, Sophos Biotech, Sosei, Sosei Heptares, Soterix Medical, Sourcia, Southern Cross University, Southern Research Institute, Spacelabs Healthcare, Spark Therapeutics, SpeechVive, Spinal Kinetics, Spinal Resources, SpineThera, Spineway, Spotlight Innovation, SPR Therapeutics, STADA Arzneimittel, Stanford University, Stanford University School of Medicine, Starr Foundation, STC.UNM, Stellar Technologies, Stem Cell Medicine, Stem Cell Network, Stemcell Technologies, StemoniX, Stevenage Bioscience Catalyst, Stevens Institute of Technology, Steve Tisch, Stimwave Technologies, St Michael's Hospital, Stony Brook University, Strand Life Sciences, Strategic Science and Technologies, StrideBio, Strides Arcolab, Stryker, SunGen, Sunovion Pharmaceuticals, Sun Pharma Advanced Research Company, Sun Pharmaceutical, SUNY Upstate Medical University, Supernus Pharmaceuticals, Surgical Solutions, Sway Medical, Swixx Biopharma, SWK Funding, SymBio Pharmaceuticals, Symbiotix Biotherapies, Synapcell, Synapse Biomedical, Synergetics, Synergy Disc Replacement (SDRI), Synergy Strips, Syngene, Synlogic, Synpromics, Syntano Technology Venture, Taconic, Taiwan Liposome Company, Takeda Pharmaceutical, Target ALS Foundation, Targeted Medical Pharma, Tasly Pharmaceuticals, Tau Consortium, Technology Strategy Board (UK), Technology University Dresden, Teijin, Teikoku Pharma USA, Teligent, Tencent Holdings, TerSera Therapeutics, Tetra Bio-Pharma, Tetragenetics, Tetraphase Pharmaceuticals, TET Systems, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, Texas Christian University, TFS Corporation, TFS International, TG Therapeutics, The American Senior Housing Association, The Consortium of Rheumatology Researchers of North America, The Cure Parkinson's Trust, The Cyprus Institute of Neurology and Genetics, The Medicines Company, The Multiple Sclerosis Association of America, The National Football League, The New York Stem Cell Foundation, Theragen, Thera Neuropharma, Theranexus, Therapeutic Solutions International, Therapix Bio, The Regents of the University of California, Thermo Fisher Scientific, The Silverstein Foundation for Parkinson's, Threshold Enterprises, Thrombolytic Science, Tikun Olam, Tissue Regeneration Systems, Titan Pharmaceuticals, Titan Spine, Tiziana Life Sciences, Tomahawk Charitable Solutions, TONIX Pharmaceuticals, Toray, Torque Medical Holdings, Torrey Pines Investment, Toshiba Medical Systems Corporation, Toulouse University Hospital, Translational Genomics Research Institute, Transparency Life Sciences, Treeway, Trevena, Trevi Therapeutics, Trident Brands, Trigemina, Trillium Therapeutics, Trulieve, Tuberous Sclerosis Alliance (TS Alliance), Twist Bioscience, twoXAR, TxCell, Tymora Analytical Operations, UbiQ, Ubiquigent, UBMD Orthopaedics, UCB, UGA Biopharma, UK Biobank, UK Dementias Research Platform, Ultragenyx Pharmaceuticals, Ultra Pain Products, Uman Diagnostics, Unilife, UniQuest, UniQure, Universidad de Cadiz, Universidad de Castilla-La Mancha, Universidad De Sevilla, Universidad de Seville, University Ann & Robert H. Lurie Children’s Hospital, University College London, University Health Network, University of Adelaide, University of Alabama, University of Alabama at Birmingham, University of Alberta, University of Antwerp, University of Barcelona, University of Bonn, University of British Columbia, University of Calgary, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Chicago, University of Colorado, University of Colorado Denver, University of Dundee, University of Edinburgh, University of Exeter, University of Florida, University of Glasgow, University of Helsinki, University of Hong Kong, University of Illinois, University of Iowa, University of Kansas, University of Kentucky, University of Konstanz, University of Leipzig, University of London, University of Maryland, University of Massachusetts, University of Massachusetts Medical School, University of Michigan, University of Michigan Medical School, University of Minnesota, University of Missouri, University of Montreal, University of Nebraska, University of New Mexico, University of New South Wales, University of North Carolina, University of North Texas Health Science Center, University of Oklahoma, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Richmond, University of Rochester, University of Sheffield


For full list of companies please contact us on

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.